Study withdrawn: extended access to fostamatinib for transplant patients never launched
NCT ID NCT05509582
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study was designed to give people who had a stem cell transplant and developed low blood cell counts (anemia, low platelets) continued access to the drug fostamatinib. Only those who responded well in a prior study were eligible. The goal was to see if they could maintain stable blood cell levels for up to 21 months. However, the study was withdrawn before enrolling any participants.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC GVHD are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Scientists investigate skin immune cells to understand Graft-Versus-Host disease
- New hope for transplant patients: drug may tame chronic GVHD without steroids
- Promising drug for Post-Transplant blood issues falls short in early trial
- Can a video visit ease chronic GVHD suffering? small study says maybe
- New immune therapy combo aims to tame chronic GVHD in Steroid-Resistant patients